Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Healthy Aging Supplement Fails in Large PD Trial (opens in a new tab)

medscape.com · 2026-10-27

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 2 supported
  • 3 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Every claim we could check holds up. Two of five claims match the study. This overall rating is based only on the claims we could check. Three claims the study doesn't address.

  • 2 supported
  • 3 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5Not coveredOverall clinical scores worsened in the NR group while improving slightly with placebo, and nonmotor symptoms and quality of life were worse with NR.View evidenceHide evidence

As statedMDS-UPDRS increased by 2.45 points with NR and decreased by 0.27 points with placebo; nonmotor symptoms had a 4.22-point adjusted difference; quality-of-life difference was -0.019

Why this verdict

The abstract profile supports the stated MDS-UPDRS changes and the NMSS adjusted difference showing greater nonmotor symptom worsening with NR. However, the claim also states that quality of life was worse with NR and gives a quality-of-life effect estimate; quality-of-life outcomes are not provided in the supplied abstract-level profile, so the full claim is not verifiable at this evidence depth.

1

Study evidence

Primary outcome (total MDS‑UPDRS parts I–III) at week 52 showed worse scores with nicotinamide riboside than placebo.Adjusted mean difference 2.72 points favoring placebo (95% CI, 0.47–4.98); P = .02

“Randomized, double-blind, placebo-controlled, phase 3 clinical trial conducted at 11 centers in Norway.”
2

Study evidence

Nonmotor symptom burden (NMSS) worsened more with nicotinamide riboside than with placebo at week 52.Adjusted mean difference 4.22 points (95% CI, 1.07–7.37); P = .009

“The 5 key secondary outcomes were the individual parts I, II, and III of the MDS-UPDRS; dopamine transporter single-photon emission computed tomography brain imaging findings; and the Non-Motor Symptoms Scale score (NMSS)”
Claim 2 of 5Not coveredNR increased blood NAD+ levels, but brain energy markers and dopamine transporter SPECT imaging showed no measurable benefit.View evidenceHide evidence

As statedbetween-group blood NAD difference of 30.00 μM

Why this verdict

The profile supports that dopamine transporter SPECT, a prespecified secondary outcome, showed no significant between-group difference. But the supplied abstract profile does not report blood NAD+ results or brain energy-marker outcomes, so those parts of the claim cannot be verified at abstract depth.

1

Study evidence

Nonmotor symptom burden (NMSS) worsened more with nicotinamide riboside than with placebo at week 52.Adjusted mean difference 4.22 points (95% CI, 1.07–7.37); P = .009

“The 5 key secondary outcomes were the individual parts I, II, and III of the MDS-UPDRS; dopamine transporter single-photon emission computed tomography brain imaging findings; and the Non-Motor Symptoms Scale score (NMSS)”
Claim 3 of 5Not coveredAdverse events were similar overall between groups, although serious adverse events were lower with NR.View evidenceHide evidence

As statedAEs 54.6% vs 53.7%; serious AEs 8.3% vs 14.1%

Why this verdict

The profile supports the serious adverse event counts as descriptively lower with NR: 17/205, 8.3%, versus 29/205, 14.1%, with placebo. However, the supplied abstract profile does not provide overall adverse-event rates or testing/precision for the SAE comparison, so the broader statement that adverse events were similar overall is not verifiable at this depth.

1

Study evidence

Serious adverse events occurred in 17 (8.3%) of 205 participants receiving nicotinamide riboside and 29 (14.1%) of 205 receiving placebo in the safety population.17/205 (8.3%) vs 29/205 (14.1%); absolute difference −5.8 percentage points (no p-value or confidence interval reported in abstract).

“Serious adverse events occurred in 17 (8.3%) of 205 participants receiving nicotinamide riboside and 29 (14.1%) of 205 receiving placebo in the safety population.”
Claim 4 of 5SupportedNicotinamide riboside, a supplement promoted for healthy aging, did not slow the progression of early Parkinson’s disease in a new phase 3 trial.View evidenceHide evidence

Why this verdict

The abstract-level profile supports that NOPARK was a randomized, double-blind, placebo-controlled phase 3 trial of oral nicotinamide riboside in early Parkinson disease and that 52-week NR did not improve clinical outcomes, with the primary MDS-UPDRS result favoring placebo. The headline's 'did not slow progression' wording is broadly consistent with the paper's conclusion that the findings do not support NR as a disease-modifying treatment, though the 'promoted for healthy aging' framing is not itself established in the supplied abstract profile.

1

Study evidence

Primary outcome (total MDS‑UPDRS parts I–III) at week 52 showed worse scores with nicotinamide riboside than placebo.Adjusted mean difference 2.72 points favoring placebo (95% CI, 0.47–4.98); P = .02

“Randomized, double-blind, placebo-controlled, phase 3 clinical trial conducted at 11 centers in Norway.”
Claim 5 of 5SupportedIn the 52-week NOPARK trial, 500 mg twice daily of NR did not improve clinical outcomes or slow clinical progression compared with placebo in participants with early Parkinson’s disease.View evidenceHide evidence

As stated52 weeks; 500 mg twice daily

Why this verdict

The profile directly supports the trial duration, dose, comparison, and population: NR 500 mg twice daily versus placebo for 52 weeks in early Parkinson disease. It also supports that NR did not improve the primary clinical outcome and was associated with worse MDS-UPDRS change than placebo.

1

Study evidence

Primary outcome (total MDS‑UPDRS parts I–III) at week 52 showed worse scores with nicotinamide riboside than placebo.Adjusted mean difference 2.72 points favoring placebo (95% CI, 0.47–4.98); P = .02

“Randomized, double-blind, placebo-controlled, phase 3 clinical trial conducted at 11 centers in Norway.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The abstract does not provide overall adverse-event rates, detailed SAE types, relatedness to study drug, timing, or statistical testing for the SAE difference.

    The story states that adverse events were similar overall and that serious adverse events were lower with NR, but the supplied abstract profile only supports SAE counts and notes missing safety-detail limitations.

    From Randomized double-blind placebo-controlled phase 3 trial; safety population analysis

  • The statistically significant primary MDS-UPDRS between-group difference was smaller than the abstract-reported clinically important worsening threshold of 5.2 points.

    The story emphasizes lack of clinical benefit and worsening with NR but does not mention this clinical-importance caveat from the abstract-level profile.

    From Randomized, double-blind, placebo-controlled phase 3 clinical trial

7 things the story did carry across
  • NOPARK was a randomized, double-blind, placebo-controlled phase 3 trial conducted at 11 centers in Norway, testing oral nicotinamide riboside 500 mg twice daily versus placebo for 52 weeks in early Parkinson disease.
  • The prespecified primary outcome was change from baseline to week 52 in total MDS-UPDRS parts I-III.
  • At week 52, total MDS-UPDRS worsened by 2.45 points with NR and improved by 0.27 points with placebo; the adjusted mean difference was 2.72 points favoring placebo.
  • The authors concluded that 52-week NR did not improve clinical outcomes and was associated with worse clinical outcomes than placebo in early Parkinson disease.
  • Nonmotor symptom burden, measured by NMSS, worsened more with NR than placebo, with an adjusted mean difference of 4.22 points.
  • Four of five prespecified key secondary outcomes showed no significant difference, including MDS-UPDRS parts I, II, III individually and dopamine transporter SPECT imaging.
  • Serious adverse events occurred in fewer participants receiving NR than placebo: 17/205, 8.3%, versus 29/205, 14.1%.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoTest whether 52-week oral nicotinamide riboside (NR) improves clinical outcomes in early-stage Parkinson disease vs placebo.Randomized, double-blind, placebo-controlled phase 3 clinical trialExpand

In plain English

Phase 3 randomized, double-blind, placebo-controlled trial (NOPARK) testing oral nicotinamide riboside (500 mg twice daily) versus matching placebo for 52 weeks in patients with early Parkinson disease. The prespecified primary outcome was change from baseline to week 52 in total MDS‑UPDRS (parts I–III) analyzed with a mixed model for repeated measures. At week 52, the adjusted mean difference in total MDS‑UPDRS favored placebo (2.72 points; 95% CI, 0.47–4.98; P = .02). Nonmotor symptom burden (NMSS) worsened more with nicotinamide riboside (adjusted mean difference 4.22 points; 95% CI, 1.07–7.37; P = .009). Four of five prespecified key secondary outcomes showed no significant differences. Serious adverse events occurred in 17/205 (8.3%) participants receiving nicotinamide riboside and 29/205 (14.1%) receiving placebo (safety population). The authors conclude that 52‑week nicotinamide riboside did not improve clinical outcomes and was associated with worse clinical outcomes than placebo in early Parkinson disease.

Key findings

  • Primary outcome (total MDS‑UPDRS parts I–III) at week 52 showed worse scores with nicotinamide riboside than placebo.Adjusted mean difference 2.72 points favoring placebo (95% CI, 0.47–4.98); P = .02
  • Nonmotor symptoms (NMSS) worsened more with nicotinamide riboside than with placebo.Adjusted mean difference 4.22 points (95% CI, 1.07–7.37); P = .009
“Randomized, double-blind, placebo-controlled, phase 3 clinical trial conducted at 11 centers in Norway.”
What this piece can’t prove
  • Abstract does not provide full details on randomization sequence generation, allocation concealment, adherence measures, or complete missing-data handling beyond use of MMRM.
  • Clinical relevance thresholds given for MDS‑UPDRS (improvement 6.7; worsening 5.2) suggest the statistically significant primary outcome difference was smaller than the reported clinically important worsening threshold; interpretation of clinical importance may require fuller data.

2 further details could not be confirmed from the summary.

2human in vivoAssess NR effects on prespecified key secondary clinical and imaging outcomes (MDS-UPDRS subparts, dopamine transporter SPECT, NMSS).Randomized, double-blind, placebo-controlled phase 3 trial (NOPARK)Expand

In plain English

In the NOPARK randomized, double-blind, placebo-controlled phase 3 trial of nicotinamide riboside (500 mg twice daily) versus placebo for 52 weeks in early Parkinson disease, five prespecified key secondary outcomes (MDS-UPDRS parts I, II, and III separately; dopamine transporter SPECT; and the Non-Motor Symptoms Scale [NMSS]) were assessed at week 52. Four of the five prespecified secondary outcomes showed no significant difference between groups, whereas nonmotor symptom burden (NMSS) worsened more with nicotinamide riboside (adjusted mean difference 4.22 points; 95% CI, 1.07–7.37; P = .009).

Key findings

  • Nonmotor symptom burden (NMSS) worsened more with nicotinamide riboside than with placebo at week 52.Adjusted mean difference 4.22 points (95% CI, 1.07–7.37); P = .009
  • MDS-UPDRS part I (individual prespecified secondary outcome) showed no significant difference between nicotinamide riboside and placebo at week 52 according to the abstract.
“The 5 key secondary outcomes were the individual parts I, II, and III of the MDS-UPDRS; dopamine transporter single-photon emission computed tomography brain imaging findings; and the Non-Motor Symptoms Scale score (NMSS)”
What this piece can’t prove

3 further details could not be confirmed from the summary.

3human in vivoEvaluate safety/tolerability of NR vs placebo over 52 weeks (serious adverse events and related safety outcomes).Randomized double-blind placebo-controlled phase 3 trial; safety population analysisExpand

In plain English

In the randomized, double-blind, placebo-controlled NOPARK phase 3 trial (52 weeks) the abstract reports counts of serious adverse events (SAEs) in the safety population: 17 of 205 participants (8.3%) assigned to nicotinamide riboside versus 29 of 205 participants (14.1%) assigned to placebo.

Key findings

  • Serious adverse events occurred in 17 (8.3%) of 205 participants receiving nicotinamide riboside and 29 (14.1%) of 205 receiving placebo in the safety population.17/205 (8.3%) vs 29/205 (14.1%); absolute difference −5.8 percentage points (no p-value or confidence interval reported in abstract).
“Serious adverse events occurred in 17 (8.3%) of 205 participants receiving nicotinamide riboside and 29 (14.1%) of 205 receiving placebo in the safety population.”
What this piece can’t prove
  • Information is limited to the abstract: lacks detailed SAE descriptions, causality/relatedness assessments, timing, and per-event vs per-participant counting.
  • The abstract does not report statistical testing (p-values or CIs) for the SAE comparison, preventing inference about the precision or statistical significance of the observed difference.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 15 candidate papers

Candidate

J012 NAD-HD: a randomized clinical trial of nicotinamide riboside in Huntington’s disease

J: Clinical Therapeutics · 2024 · Crossref

Source (opens in a new tab)

And 9 more candidates considered.